悦康药业 (688658.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−203.4x

Market Cap

CNY 5.95B

MomentumView details →

1D Return

−7.69%

YTD Return

—

RSI (14)

49.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−203.4x

Market Cap

CNY 5.95B

RSI (14)

49.4

MomentumView details →

1D Return

−7.69%

YTD Return

—

ProfitabilityView details →

Gross Margin

53.03%

Net Margin

−10.15%

EBITDA Margin

−1.18%

ROE (TTM)

−7.50%

ROA (TTM)

−4.75%

Asset Turnover

0.47x

GrowthView details →

Revenue YoY

−28.48%

EPS YoY

—

FCF YoY

+318.74%

Revenue CAGR 3Y

−18.64%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−CNY 0.16

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.17x

Current Ratio

1.97x

Quick Ratio

1.60x

Div Yield

—

Div Rate

—

Div Growth 1Y

−81.82%

Financials snapshotView financials →

Revenue (TTM)

2.42B

Net Income (TTM)

−246.22M

Op. CF (TTM)

303.72M

Latest newsMore news →

Yuekang Pharmaceutical announced it will invest 45 million yuan of excess raised funds into a small nucleic acid drug R&D project, covering three investigational drugs.15d ago

Yuekang Pharmaceutical announced its first-half 2026 results, reporting a net loss attributable to shareholders of 105 million yuan, compared with a loss of 98.8291 million yuan in the same period last year.15d ago

Similar companies

Cogent Biosciences, Inc.COGT 科前生物688526.SH Dianthus Therapeutics, Inc.DNTH PTC Therapeutics, Inc.PTCT Kiniksa Pharmaceuticals, Ltd.KNSA Xenon Pharmaceuticals Inc.XENE Find similar companies →

Latest newsMore news →

Yuekang Pharmaceutical announced it will invest 45 million yuan of excess raised funds into a small nucleic acid drug R&D project, covering three investigational drugs.15d ago Yuekang Pharmaceutical announced its first-half 2026 results, reporting a net loss attributable to shareholders of 105 million yuan, compared with a loss of 98.8291 million yuan in the same period last year.15d ago